Company intelligence / Profile preview
Adze Biotechnology
Coral Gables, Florida, United Statesadzebiotech.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Adze Biotechnology has developed a proprietary oncolytic adenovirus platform (Adze‑1.17) designed for systemic delivery of immune-stimulatory payloads and checkpoint inhibitors directly to tumors. The company’s approach aims to overcome the limitations of current checkpoint inhibitor therapies by directly lysing tumor cells, releasing neoantigens, and stimulating both innate and adaptive immune responses. Preclinical results show promise in generating robust anti-tumor immunity with a favorable safety profile. Orphan Drug Designation has been granted for at least one candidate therapy targeting rare cancers.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusesCheckpoint inhibitorsImmune-stimulatory transgenes
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Adze Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adze Biotechnology.